Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2009
12/01/2009US7625925 Pyrazolo[1,5-a]pyridines and medicines containing the same
12/01/2009US7625919 Osteoporosis; oral diseases; bone disorders; atherosclerosis; antiarthritic agents; autoimmune disease; cachexia
12/01/2009US7625914 2(S)-Ethoxy-3-{4-[2-(3-heptyl-1-methylureido)thiazol-4-yl]phenyl}propanoic acid; dermatology, and cardiovascular diseases, immune diseases, lipid metabolism diseases; veterinary medicine
12/01/2009US7625913 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
12/01/2009US7625907 administering a drug of 1,5-bis(3-nitrooxypropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, for heart failure and stable angina, cardiovascular disorders
12/01/2009US7625892 Pharmaceutical compositions for the treatment of diseases related to neurotrophines
12/01/2009US7625887 e.g. 2-[3,5-trans-5-(3-aminophenyl)-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide; G-protein-coupled receptor (TGR5) agonist; central nervous system diseases; antiinflammatory agent; learning enhancement; angina pectoris, arrhythmia, bronchial asthma
12/01/2009US7625883 Choline Salt of L- alpha -glycero-phospho-D-mio-inositol; alpha -glycero-phospho-D-mio-inositol tetrabutylammonium salt; treatment of pathologies mediated by the activation or over stimulation of cytololilc phospholipase-2 (PLA2), particularly, septic shock and viral and bacterial infections
12/01/2009US7625882 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
12/01/2009US7625881 3-ethyl-2,6-dioxo-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurin-7-yl]methyl butanoate; treatment of asthma and diarrhea
12/01/2009US7625713 Process for identifying a ligand that binds to the NEP binding site for the SMR1 pentapeptide
12/01/2009US7625696 Method and screening kit using a GPR30 receptor and a ligand capable of specifically binding to receptor, a compound which is obtainable using screening method or kit; particularly relates to screening method and screening kit for prevention/treatment of cancer, heart disease
12/01/2009US7625562 Generation of cartilage using magnetizable particles
12/01/2009CA2461100C 4-imidazolin-2-one compounds
12/01/2009CA2432121C Nitric oxide synthase inhibitor phosphate salt
12/01/2009CA2418348C Oil/fat composition
12/01/2009CA2401878C Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation
12/01/2009CA2389412C N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
12/01/2009CA2384718C Prostaglandin derivatives
12/01/2009CA2265547C Method of treating endothelial injury
11/2009
11/26/2009WO2009143403A1 Combination therapy for the management hypertension
11/26/2009WO2009143363A2 Functional metabolomics coupled microfluidic chemotaxis device and identification of novel cell mediators
11/26/2009WO2009143049A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
11/26/2009WO2009142988A2 Chitin micro-particles as an adjuvant
11/26/2009WO2009142699A1 Treatment of heart failure in women
11/26/2009WO2009142679A2 Methods for treating acute myocardial infarction
11/26/2009WO2009142321A1 Novel thiophenediamine derivative having urea structure
11/26/2009WO2009142319A1 Vascular aging inhibitor and anti-aging formulation
11/26/2009WO2009142242A1 Composition for preventing cardiovascular event in high-risk patient
11/26/2009WO2009141167A1 Bosentan salts
11/26/2009WO2009140928A1 Dihydroindolinone derivatives
11/26/2009WO2009140887A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof
11/26/2009WO2009140886A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof
11/26/2009WO2009140863A1 Compositions comprising quinazoline derivatives, preparation methods and uses thereof
11/26/2009WO2009140724A1 Herg mutants and uses thereof
11/26/2009WO2009125231A3 Anti-atheroma vaccine
11/26/2009WO2009116774A3 Composition for treatment or prevention of restenosis
11/26/2009WO2009115331A3 Protein product for modifying cardiovascular health
11/26/2009WO2009079679A3 Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
11/26/2009WO2009043458A3 Use of oxytocin to treat many diseases
11/26/2009WO2009043457A3 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis
11/26/2009WO2009040024A3 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections
11/26/2009WO2009039981A3 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection
11/26/2009WO2009039980A3 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection
11/26/2009WO2009033820A3 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
11/26/2009WO2009033783A3 Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis
11/26/2009WO2009033782A3 Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
11/26/2009US20090292016 Stable Pharmaceutical Compositions Containing Pravastatin
11/26/2009US20090292000 Pyrrolidine derivatives as prostaglandin modulators
11/26/2009US20090291999 Agent Exhibiting a Neurotropic, Neuromodulator, Cerebrovascular and Anti-Stroke Activity
11/26/2009US20090291997 Carvedilol dihydrogen phosphate monohydrate
11/26/2009US20090291980 Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
11/26/2009US20090291974 Bosentan salts
11/26/2009US20090291963 Substituted indoles
11/26/2009US20090291958 Substituted PDE5 inhibitors
11/26/2009US20090291957 Heterocyclic derivatives and their use as therapeutic agents
11/26/2009US20090291948 Sulfonamide peri-substituted bicyclics for occlusive artery disease
11/26/2009US20090291946 Lactam compounds and their use as pharmaceuticals
11/26/2009US20090291933 Solid state forms of a pharmaceutical
11/26/2009US20090291917 Boron-Containing Small Molecules as Anti-Inflammatory Agents
11/26/2009US20090291916 Trihydroxy Polyunsaturated Eicosanoid
11/26/2009US20090291154 pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof
11/26/2009US20090291126 Adhesive pharmaceutical preparation containing bisoprolol
11/26/2009US20090291111 Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
11/26/2009US20090291102 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
11/26/2009US20090291100 Therapeutic agent for polycystic ovary syndrome (pcos)
11/26/2009US20090291061 Stem cell therapy for blood vessel degeneration
11/26/2009US20090291050 Particulate materials
11/26/2009DE10234192B4 Verwendung von Erythropoetin Use of erythropoietin
11/26/2009CA2725001A1 Dihydroindolone derivatives
11/26/2009CA2724983A1 Composition for preventing cardiovascular event in high-risk patient
11/26/2009CA2724700A1 Herg mutants and uses thereof
11/26/2009CA2724426A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
11/26/2009CA2724357A1 Novel thiophenediamine derivative having urea structure
11/25/2009EP2123752A2 Novel nucleic acid
11/25/2009EP2123751A1 Novel peptide
11/25/2009EP2123674A1 Treatment of fibrosis by antagonism of IL-13 and/or IL-13 receptor
11/25/2009EP2123652A1 Heterocyclic compound
11/25/2009EP2123649A1 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof
11/25/2009EP2123630A1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
11/25/2009EP2123303A1 Ameliorating agent for insulin resistance
11/25/2009EP2123293A2 Peptide YY and petide YY agonists for treatment of metabolic disorders
11/25/2009EP2123292A1 Angiogenically effective unit dose of FGF-2 and method of use
11/25/2009EP2123284A1 Prophylactic and/or therapeutic agent for cardiac infarction
11/25/2009EP2123171A1 Feed mixture
11/25/2009EP2121750A2 Inflammation treatment, detection and monitoring via trem-1
11/25/2009EP2121668A2 6,8-dichlorchroman-3-yl-1,3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
11/25/2009EP2121652A1 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
11/25/2009EP2120968A1 Use of d-ribose to treat cardiac arrhythmias
11/25/2009EP2120954A1 Adenosine derivatives as partial and full agonists of a1 adenosine receptors
11/25/2009EP2120947A1 Use of nicotinamide for treatment and/or prevention of arteriosclerosis
11/25/2009EP2120919A1 New combination for use in the treatment of inflammatory disorders
11/25/2009EP2120909A2 Treatments of therapy-resistant diseases comprising drug combinations
11/25/2009EP1776099B1 Methods for improving bioavailability of a renin inhibitor
11/25/2009EP1729788B1 Restenosis therapy using mesenchymal stem cells
11/25/2009EP1482932B1 N3 alkylated benzimidazole derivatives as mek inhibitors
11/25/2009EP1242385B1 Cytokine, especially tnf-alpha, inhibitors
11/25/2009EP1210108B1 Use of leptin together with an inhibitor of vegf and/or an inhibitor of angiogenesis for the inhibition of endothelial cell proliferation
11/25/2009EP1144405B1 Triazole compounds with dopamine-d3-receptor affinity
11/25/2009EP1019490B1 Methods for modulating hematopoiesis and vascular growth
1 ... 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 ... 1595